CD274 and neoplasm: This checkpoint blockade therapy has mainly focused on treatments targeting surface proteins, programmed cell death 1 (PD-1), its ligand, programmed cell death ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), that have resulted in tumor regression in certain cancer patients.